Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Guangzhou Kingmed Diagnostics Group Co Ltd
Gross Profit
Guangzhou Kingmed Diagnostics Group Co Ltd
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
|
Gross Profit
¥2.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
G
|
Gushengtang Holdings Ltd
HKEX:2273
|
Gross Profit
¥1B
|
CAGR 3-Years
27%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Topchoice Medical Co Inc
SSE:600763
|
Gross Profit
¥1.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
13%
|
|
|
Nanjing Xinjiekou Department Store Co Ltd
SSE:600682
|
Gross Profit
¥2.8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-6%
|
|
|
Dian Diagnostics Group Co Ltd
SZSE:300244
|
Gross Profit
¥3B
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
18%
|
|
|
Meinian Onehealth Healthcare Holdings Co Ltd
SZSE:002044
|
Gross Profit
¥4.4B
|
CAGR 3-Years
9%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
Glance View
Guangzhou Kingmed Diagnostics Group Co Ltd has crafted its journey in the healthcare industry with precision and analytical prowess. Emerging in the early 2000s, Kingmed Diagnostics tapped into a burgeoning market niche—offering diagnostic testing services to hospitals, clinics, and other medical institutions. With a blend of advanced technology and extensive scientific expertise, the company provides a range of services, from routine clinical testing to esoteric evaluations that require more sophisticated techniques. Kingmed’s laboratories, strategically established across China, facilitate a seamless operation that processes millions of tests annually, ensuring timely and accurate results. This operational efficiency not only supports healthcare providers in delivering informed patient care but also positions Kingmed at the forefront of diagnostic innovation. Revenue streams flow through service contracts with healthcare facilities and direct partnerships where they provide specialized testing offerings that institutions may not have the infrastructure to perform in-house. By leveraging economies of scale, Kingmed achieves cost efficiencies, which in turn afford competitive pricing structures, further securing its market position. Complementing its robust diagnostic services, the company also invests in research and development initiatives, continuously enhancing its test portfolio. This commitment to innovation ensures that they stay relevant in the ever-evolving healthcare landscape, capturing new opportunities and expanding their market reach. Through this strategic framework, Guangzhou Kingmed Diagnostics not only sustains its financial growth but also fortifies its leadership in the diagnostic services sector.
See Also
What is Guangzhou Kingmed Diagnostics Group Co Ltd's Gross Profit?
Gross Profit
2.1B
CNY
Based on the financial report for Mar 31, 2026, Guangzhou Kingmed Diagnostics Group Co Ltd's Gross Profit amounts to 2.1B CNY.
What is Guangzhou Kingmed Diagnostics Group Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 5Y
-15%
Over the last year, the Gross Profit growth was -9%. The average annual Gross Profit growth rates for Guangzhou Kingmed Diagnostics Group Co Ltd have been -28% over the past three years , -15% over the past five years .